What the FDA labels say about taking them together
Darunavir and ethinyl estradiol/norelgestromin
Ethinyl estradiol/norelgestromin's FDA label of April 16, 2026 names darunavir in its drug interactions section; the darunavir label PlainMeds reads does not name ethinyl estradiol/norelgestromin. The ethinyl estradiol/norelgestromin label: “Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors Significant changes (increase or decrease) in the plasma concentrations of estrogen …”
Check it at the source: the darunavir FDA label on DailyMed (effective August 29, 2025, Janssen Products LP); the ethinyl estradiol/norelgestromin FDA label on DailyMed (effective April 16, 2026, Zydus Pharmaceuticals USA Inc.).
What does the darunavir label say about ethinyl estradiol/norelgestromin?
Darunavir's label (effective August 29, 2025) does not name ethinyl estradiol/norelgestromin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (PREZISTA), Janssen Products LP, effective August 29, 2025 (SPL set 814301f9-c990-46a5-b481-2879a521a16f), via openFDA; the full label on DailyMed
What does the ethinyl estradiol/norelgestromin label say about darunavir?
Ethinyl estradiol/norelgestromin label, drug interactionsHuman Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritnoavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]).
Gwyn Lo label (Viatris Specialty LLC, July 6, 2026), drug interactionsSignificant decreases in systemic exposure of the estrogen and/or progestin have been noted when CHCs are co-administered with some HIV protease inhibitors (e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir), some HCV protease inhibitors (e.g., boceprevir and telaprevir), and some non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine).
Source: FDA drug label (Gwyn Lo, NDA219990), Viatris Specialty LLC, effective July 6, 2026 (SPL set e92741f4-87fe-429f-b5b5-c558ed5f4fa9), via openFDA
Source: FDA drug label (norelgestromin and ethinyl estradiol), Zydus Pharmaceuticals USA Inc., effective April 16, 2026 (SPL set 10fa1458-c8ed-4197-922a-1ba7271d2b02), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Darunavir | Ethinyl estradiol/norelgestromin | |
|---|---|---|
| Labeled for | HIV | Birth control |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.16 per tablet 600 mg tablet | $37.16 per patch 150-35 mcg/day patch |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once